Targeted therapy in head and neck cancer
- 28 April 2008
- Vol. 112 (12), 2635-2645
- https://doi.org/10.1002/cncr.23521
Abstract
In patients with squamous cell carcinoma of the head and neck (SCCHN), tumor recurrence, secondary tumors, and comorbidities contribute to therapy failure, and treatment approaches often are limited by their toxicity. With the incorporation of targeted therapies, the number of options available for patients with SCCHN is growing. The epidermal growth factor receptor (EGFR) is involved in the development and progression of SCCHN and is associated with a poor prognosis. The anti‐EGFR monoclonal antibody (MoAb) cetuximab is the first targeted therapy to be developed for SCCHN. Recent data confirmed a survival advantage and enhanced locoregional control of SCCHN with cetuximab plus radiotherapy (RT) in patients with locally advanced (LA) SCCHN. Single‐agent cetuximab conferred clinical benefits for patients with platinum‐refractory metastatic disease, and a recent phase 3 trial demonstrated a survival benefit with cetuximab and standard platinum‐based therapy in the front‐line treatment of recurrent/metastatic disease. Cetuximab has a toxicity profile milder than that of cytoxic agents and does not exacerbate RT toxicity when it is used in combination. Small‐molecule EGFR‐tyrosine kinase inhibitors also have shown promise in combination with chemoradiotherapy or as single agents, although they are in earlier stages of developmental. Other targeted approaches (eg, antiangiogenics) are also under investigation. Ongoing clinical trials will further define targeted treatment roles in all stages of SCCHN. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 84 references indexed in Scilit:
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidinesJournal of Clinical Oncology, 2006
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysisThe Lancet, 2006
- Biological agents in head and neck cancerAnnals of Oncology, 2006
- Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein KinasePublished by Elsevier BV ,2005
- The role of cetuximab in the treatment of squamous cell cancer of the head and neckExpert Opinion on Biological Therapy, 2005
- Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapyEuropean Journal of Cancer, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancerInternational Journal of Cancer, 2003
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy & Radiopharmaceuticals, 1999